Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease.
Fiche publication
Date publication
mai 2015
Journal
Inflammatory bowel diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Bouguen G, Laharie D, Nancey S, Hebuterne X, Flourie B, Filippi J, Roblin X, Trang C, Bourreille A, Babouri A, Bretagne JF, Siproudhis L, Peyrin-Biroulet L
Lien Pubmed
Résumé
In case of a loss of response to adalimumab, some patients with Crohn's disease may derive benefit from increasing the dosing frequency to 40 mg weekly. Efficacy and safety of adalimumab 80 mg weekly remain unknown.
Mots clés
Adalimumab, therapeutic use, Adult, Anti-Inflammatory Agents, therapeutic use, Crohn Disease, drug therapy, Female, Follow-Up Studies, Humans, Male, Prognosis, Prospective Studies, Remission Induction, Safety
Référence
Inflamm. Bowel Dis.. 2015 May;21(5):1047-53